How AstraZeneca plc Could Struggle To Repeat A 5-Year Gain of 78%

AstraZeneca plc (LON:AZN) could loose a third of its value in the next five years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The shares of AstraZeneca (LSE: AZN) (NYSE: AZN.US), currently trading at around £46, have soared 78% over the last five years, outperforming the FTSE 100, which has gained 53%.

A good chunk of the gain has come on the back of the recent takeover offer from US giant Pfizer. Before rumours of the offer emerged, AstraZeneca’s shares were trading below £38.

While investors buying into the UK firm today at £46 could potentially see a relatively quick gain of 20% if Pfizer sweetened its £50 bid to £55 — and was successful, of course — they could equally see a sharp 20% reversal back to below £38 if the deal failed to go ahead.

Should you invest £1,000 in Hss Hire Group Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Hss Hire Group Plc made the list?

See the 6 stocks

Furthermore, I think the shares have the potential to be 33% lower than today’s price in five years’ time.

Here’s how

AZN

As most readers will know by now, AstraZeneca’s revenue and earnings have been falling over the last couple of years, due to expiring patent protection on some of its blockbuster drugs. Furthermore, City analysts don’t expect the declines to bottom out until 2017, when earnings per share (EPS) is expected to floor at around 234p.

With last year’s EPS at 306p, and EPS for the year ending December 2018 forecast to be 253p, we’re looking at a compound annual growth rate of minus 3.7%.

If we were generous, and rated AstraZeneca’s 2018 EPS of 253p at the FTSE 100’s long-term average historic P/E of 16, we’d see the share price at around £40.50 — 12% lower than today.

Gloomy scenario

But, if takeover talk was off the agenda, and the gloomy earnings scenario played out according to analysts’ forecasts, it wouldn’t be too hard to imagine AstraZeneca rated on the P/E it was at before Pfizer’s recent interest; namely 12.3. If that were to be the case, the shares would be trading at not much more than £31 five years from now — 33% lower than today.

The negative return would be mitigated by dividends, although the most bearish analysts are forecasting a cut within the next couple of years. Still, taking the consensus, we’d see 844p paid out over the period. Put another way, a £1,000 investment in AstraZeneca today would deliver £184 in dividends. Pretty decent income, but little compensation for a potential capital fall of 33%.

Long-term shareholders who’ve cashed-in for a good return on the back of Pfizer’s offer will be delighted, but anyone buying into AstraZeneca at the current price faces the risk of a short, sharp shock and a very long-haul recovery if the takeover goes pear-shaped.

Like buying £1 for 31p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester does not own any shares mentioned in this article.

More on Investing Articles

Investing Articles

Just released: our 3 top small-cap stocks to consider buying in April [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

Here’s why Tesla stock just rocketed 22.7%! Is it time to buy?

This writer wonders whether the news that sent Tesla stock soaring yesterday is a true gamechanger for the electric vehicle…

Read more »

Investing Articles

2 quality UK stocks to consider buying as share prices rally

With UK stocks moving higher, it might look as though investors with cash on hand have missed their chance. But…

Read more »

Investing Articles

How much £10,000 invested in Lloyds shares is forecast to be worth in 12 months

Harvey Jones is looking past today's stock market volatility to see where Lloyds shares may stand in a year's time.…

Read more »

Investing Articles

How Warren Buffett stays ahead of the stock market

When share prices fall, everyone suddenly wants to be like Warren Buffett. But what’s the secret to the Berkshire Hathaway…

Read more »

Investing Articles

Cheap UK dividend shares to consider buying right now

We're only just past the first quarter of 2025, but it already looks like the year could be another good…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

What the heck is going on with the Barclays share price now?

The Barclays share price surged 25% as the market open on 10 April. Once again, the volatility’s been driven by…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

What the devil’s going on with the HSBC share price?

The HSBC share price has actually been less volatile than some of its peers, despite its Chinese operations suggesting it’s…

Read more »